European Study of Prodromal iNPH
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorJohan Virhammar
About this trial
To investigate if progression from prodromal into symptomatic NPH can be predicted from advanced neuroimaging, biomarkers in cerebrospinal fluid (CSF) and plasma and investigate the unknown mechanisms causing deterioration by investigating longitudinal changes in the above-mentioned variables. Three different cohorts with both asymptomatic and symptomatic patients as well as healthy controls will be investigated over time, both without intervention and before and after shunt surgery.
Eligibility criteria
Qualifiers
Group 1 - prodromal iNPH
Evans index > 0.3
Disproportionately enlarged subarachnoid space hydrocephalus (DESH) - defined as: enlarged ventricles, dilated sylvian fissures and tight sulci at the high convexity.
Normal gait pattern, or slight disturbance of the gait pattern that is not considered to be caused by a disease in the central nervous system (CNS).
Disqualifiers
Group 1 - prodromal iNPH
Contraindication for MRI
Other serious disease with expected survival less than three years
non-communicating hydrocephalus
Trial design
Treatments tested in this trial
- Shunt surgery
Treatment groups
140 Participants
are divided into 3 treatment groupsSponsors and collaborators
Johan Virhammar
Lead sponsor
Uppsala University Hospital
Sponsor institution
Swedish Society for Medical Research
Collaborator
Source ClinicalTrials.gov